ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Real-world safety of voretigene neparvovec: a disproportionality analysis for signal detection using the FAERS database.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the post-marketing safety profile of voretigene neparvovec using a large spontaneous reporting database. This is a. retrospective pharmacovigilance disproportionality study. Adverse event (AE) reports for voretigene neparvovec were retrieved from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), Q1 2019-Q1 2025. Disproportionality was assessed using reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM). Signals were summarized at the System Organ Class (SOC) and Preferred Term (PT) levels. A total of 128 AE reports were included. The median patient age was 18 years, with adolescents and young adults comprising the majority. The primary sources of reports were physicians (44.53%) and consumers (43.75%), with intraocular injection being the most frequently reported route of administration (25.00%). Signal analysis revealed that ocular disorders had the highest number of reports and the most prominent signal strength (e.g., retinal degeneration: ROR = 3742.02, IC025 = 6.93; retinal depigmentation: ROR = 8865.67, IC025 = 8.37). Other significant signals included vitreous floaters (ROR = 1497.43, IC025 = 5.43) and elevated intraocular pressure (ROR = 473.10, IC025 = 4.37). In contrast, systemic events such as headache and ocular pain showed weaker signals that did not exceed the statistical significance threshold. In real-world use, voretigene neparvovec is mainly associated with ocular AEs linked to surgical delivery and local inflammatory responses, notably structural retinal changes and intraocular pressure elevations. These findings support careful preoperative assessment, optimized perioperative technique, and close postoperative monitoring. FAERS-based signals indicate association rather than causality and should be interpreted alongside prospective data. Clinical trial number is not applicable.
Indexed as
Identifiers
41758347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.